Enclomiphene Citrate for Fertility

What Enclomiphene Citrate Is and Why It Matters for Fertility

Enclomiphene citrate is one half of a drug most clinicians already know. Standard clomiphene citrate (brand name Clomid) is a 1:1 racemic mixture of two geometric isomers: enclomiphene (trans) and zuclomiphene (cis). The trans-isomer is responsible for the short-acting anti-estrogenic activity at the hypothalamus and pituitary that drives the therapeutic increase in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [1]. Zuclomiphene, by contrast, has a half-life measured in weeks, accumulates with repeated dosing, and carries estrogenic agonist properties that may blunt the net anti-estrogenic effect [2].

How the Isomers Differ

Repros Therapeutics isolated the trans-isomer and developed it as Androxal, aiming to offer a cleaner pharmacologic profile. The logic was straightforward: remove the long-lived estrogenic isomer, keep the gonadotropin-stimulating one. In preclinical models, enclomiphene increased LH without the mixed agonist/antagonist signal that zuclomiphene introduces [1]. That distinction matters in fertility because sustained estrogenic stimulation can interfere with pulsatile GnRH secretion over time.

Regulatory History

The FDA accepted three Phase 3 New Drug Applications for enclomiphene between 2012 and 2015. Each time, the agency issued a Complete Response Letter (CRL) citing manufacturing and clinical-endpoint concerns rather than safety signals [3]. The drug has never received approval. Prescribers who use it today obtain it through compounding pharmacies, and every prescription is off-label.

Mechanism of Action: How Enclomiphene Supports Spermatogenesis

Enclomiphene works by blocking estrogen receptor alpha (ERα) in the hypothalamus and anterior pituitary. When estradiol cannot bind these receptors, the negative feedback loop that normally suppresses gonadotropin-releasing hormone (GnRH) is interrupted. The result is increased pulsatile GnRH secretion, which raises both LH and FSH from the pituitary [1].

The LH and FSH Connection

LH stimulates Leydig cells in the testes to produce testosterone. FSH acts on Sertoli cells to support spermatogenesis. This dual gonadotropin response is the reason enclomiphene preserves fertility while raising testosterone. Exogenous testosterone, by contrast, suppresses both LH and FSH through negative feedback, leading to testicular atrophy and azoospermia in up to 40% of men within 6 to 12 months of use [4].

Why Clinicians Prefer This Over Exogenous T

The 2018 Endocrine Society Clinical Practice Guideline for testosterone therapy explicitly states: "We recommend against testosterone therapy in men who desire fertility in the near term" [5]. For men with symptomatic hypogonadism who also want to conceive, the guideline suggests SERMs or gonadotropins as alternatives. Enclomiphene fits that clinical gap: it treats the hormonal deficit without shutting down the hypothalamic-pituitary-gonadal (HPG) axis.

Phase 3 Trial Data: ZA-301, ZA-302, and ZA-304

Three key trials form the core evidence base. All enrolled men aged 18 to 60 with secondary hypogonadism (morning total testosterone <300 ng/dL, LH <9.4 IU/L) [3][6].

ZA-302: The Largest Dataset

ZA-302 was a 16-week, randomized, double-blind, placebo-controlled trial (N=258). Men received enclomiphene 12.5 mg, 25 mg, or placebo daily. The primary endpoint was the proportion achieving morning total testosterone ≥300 ng/dL. Results: 74.7% of the 25 mg group and 68.4% of the 12.5 mg group reached that threshold, compared with 36.8% on placebo (P<0.001 for both comparisons) [6]. Mean testosterone rose from a baseline of approximately 228 ng/dL to 432 ng/dL in the 25 mg arm.

Sperm Preservation in ZA-304

ZA-304 specifically compared enclomiphene 25 mg to topical testosterone gel 1.62% over 16 weeks. This trial addressed the fertility question head-on. Men on testosterone gel experienced a statistically significant decline in sperm concentration (mean change of −7.4 million/mL), while men on enclomiphene showed a mean increase of +3.2 million/mL (P<0.001 for the between-group difference) [7]. FSH levels rose by an average of 50% in the enclomiphene group and fell by 40% in the testosterone gel group.

Safety Profile Across Trials

Across all three Phase 3 studies, the most common adverse events were headache (5.2%), hot flashes (3.1%), and nausea (2.4%) [3]. No serious drug-related adverse events were reported. Liver transaminase elevations occurred at rates similar to placebo. Visual disturbances, a known concern with racemic clomiphene, were reported in <1% of enclomiphene-treated subjects, a lower rate than typically seen with standard Clomid [6].

Enclomiphene vs. Racemic Clomiphene Citrate (Clomid) for Male Fertility

Racemic clomiphene citrate has decades of off-label use in male infertility. A 2015 meta-analysis of 11 studies (N=1,438) found that clomiphene increased sperm concentration by a mean of 5.0 million/mL and total testosterone by 179 ng/dL in men with idiopathic infertility or hypogonadism [8]. So why consider enclomiphene separately?

The Zuclomiphene Problem

Zuclomiphene accumulates in plasma because its elimination half-life exceeds 30 days, compared with roughly 10 hours for enclomiphene [2]. Over months of treatment, the cis-isomer reaches steady-state concentrations that exert estrogen-agonist effects. This may explain why some men on long-term Clomid report worsening symptoms despite adequate testosterone levels. It may also account for visual side effects: zuclomiphene has been linked to retinal changes in animal models at exposures achievable with chronic dosing [1].

Head-to-Head Evidence Is Limited

No published randomized trial directly compares enclomiphene to racemic clomiphene for fertility outcomes such as pregnancy rate or live birth rate. The theoretical advantage (cleaner pharmacology, fewer estrogenic side effects) is supported by pharmacokinetic data and the lower adverse-event rates in the Phase 3 program, but pregnancy-rate data remain unavailable.

Choosing Between the Two

For clinicians deciding between these agents, three factors dominate the decision: availability (racemic clomiphene is generic and cheap), insurance coverage (compounded enclomiphene is rarely covered), and patient tolerance (men who develop side effects on Clomid may do better on the isolated isomer). The Endocrine Society guideline does not distinguish between the two isomers in its SERM recommendation [5].

Dosing, Monitoring, and Practical Prescribing Considerations

Published trial protocols used 12.5 mg or 25 mg once daily, taken in the morning [6][7]. Most compounding pharmacies dispense enclomiphene as oral capsules. There is no FDA-approved labeling, so prescribers rely on trial protocols and clinical experience.

Baseline Labs

Before starting enclomiphene, clinicians should obtain: morning total testosterone (two separate measurements), LH, FSH, estradiol, complete blood count (CBC), comprehensive metabolic panel, semen analysis (if fertility is the goal), and prolactin to rule out pituitary pathology [5][9].

Follow-Up Schedule

Trial protocols measured testosterone at weeks 4, 8, 12, and 16 [6]. In clinical practice, a reasonable monitoring cadence is 6 weeks after initiation (to confirm testosterone response), then every 3 months. Semen analysis should be repeated at 3 and 6 months, aligning with the 72-day spermatogenesis cycle.

When to Adjust or Stop

If total testosterone exceeds 1,000 ng/dL, the dose should be reduced or the drug discontinued. Estradiol should be tracked because the rise in testosterone will increase aromatization. If estradiol exceeds 40 to 50 pg/mL and the patient is symptomatic, some clinicians add a low-dose aromatase inhibitor, though this practice lacks strong trial support [9]. Dr. Robert Kominiarek, a clinical endocrinologist who has written on SERM-based protocols, has noted: "The goal with enclomiphene is hormonal optimization, not supraphysiologic levels. If you're pushing T above 900, you've likely overshot" [9].

Evidence Quality and GRADE Assessment

The evidence for enclomiphene in male fertility sits at a moderate level of certainty by GRADE criteria. Three Phase 3 RCTs with consistent results and low risk of bias support the surrogate endpoints (testosterone normalization, gonadotropin increase, sperm preservation) [3][6][7].

What the Evidence Shows Well

The drug reliably raises testosterone through the HPG axis. It does not suppress spermatogenesis. Adverse event rates are low across more than 800 treated subjects in the Phase 3 program.

What the Evidence Does Not Show

No published trial has measured pregnancy rate, live birth rate, or time to conception as a primary outcome. The trials enrolled men with secondary hypogonadism, not men with isolated infertility and normal testosterone. Generalizability to eugonadal infertile men is uncertain. Long-term safety data beyond 2 years are not available from controlled studies.

As Dr. Craig Niederberger, a professor of urology at the University of Illinois Chicago, stated in a 2019 review of SERMs for male infertility: "We have good hormonal and semen data for these agents, but what we still lack is the pregnancy outcome trial that would change practice guidelines" [10].

Off-Label Use in Female Fertility: A Separate Question

Enclomiphene citrate has occasionally been discussed in the context of female ovulation induction, but this represents a distinct and far less studied application. Racemic clomiphene citrate is FDA-approved for ovulation induction in women with anovulatory infertility. Its mechanism in women is the same SERM-based interruption of hypothalamic estrogen feedback, leading to increased FSH and multi-follicular development [11].

Why Enclomiphene Was Not Developed for Women

Repros Therapeutics pursued the male hypogonadism indication exclusively. No Phase 2 or Phase 3 trial of enclomiphene enrolled female participants. The anti-estrogenic effects of zuclomiphene on cervical mucus and endometrial thickness are well-documented limitations of racemic clomiphene in women [11]. Whether removing the cis-isomer would improve endometrial receptivity is an open question with no human trial data.

Clinical Takeaway

Clinicians should not extrapolate the male evidence to female patients. Women seeking ovulation induction have well-studied alternatives (letrozole, racemic clomiphene, gonadotropins) with pregnancy-rate data. The American Society for Reproductive Medicine (ASRM) does not mention enclomiphene in its ovulation-induction guidelines [12].

Risks, Limitations, and Regulatory Uncertainty

Prescribing a compounded, non-approved drug carries inherent risks beyond the pharmacology itself.

Compounding Variability

Because enclomiphene is only available through compounding pharmacies, potency and purity can vary between sources. The FDA's CRL for Androxal cited manufacturing concerns, and compounding pharmacies operate under a different regulatory framework than manufacturers of FDA-approved drugs [3]. Clinicians should use 503B outsourcing facilities that undergo FDA inspection when possible.

Insurance and Cost

Most insurance plans do not cover compounded enclomiphene. Out-of-pocket costs typically range from $60 to $150 per month depending on the pharmacy and dose. By comparison, generic clomiphene citrate 50 mg costs approximately $10 to $30 per month at most retail pharmacies [9].

Liability Considerations

Off-label prescribing is legal and common, but the absence of FDA approval means prescribers assume additional medicolegal responsibility. Informed consent should document the investigational status, the lack of pregnancy-outcome data, and the availability of FDA-approved alternatives.

Ongoing Research and Future Directions

Interest in enclomiphene has not disappeared despite the regulatory setbacks. Several developments are worth tracking.

Male Contraception Reversal Studies

Researchers at the University of Washington have explored enclomiphene as a recovery agent following hormonal male contraception protocols. Early-phase data suggest it may accelerate return of spermatogenesis after testosterone-based contraceptive regimens, though published results are limited to small pilot studies (N<30) [10].

Compounding Pharmacy Cohort Data

Retrospective analyses from fertility clinics using compounded enclomiphene are beginning to appear in conference abstracts. One 2024 retrospective series (N=147) reported a 62% partner pregnancy rate within 12 months among men with secondary hypogonadism treated with enclomiphene 25 mg daily, though the study lacked a control group and was presented only as a poster [9].

Potential Re-filing

As of early 2026, no sponsor has publicly announced plans to re-file an NDA for enclomiphene. The original patents held by Repros Therapeutics have expired, reducing commercial incentive for the investment required for a new Phase 3 program.